aidot

[View original text]

Artificial intelligence cervical cancer diagnosis solution 'Cerviray AI' enters the Indonesian market.

AIDOT succeeded in registering and commercializing licenses in Indonesia.

On 19th of April, AIDOT (CEO Jae-hoon Jeong) announced that its artificial intelligence (AI) diagnosis system for cervical cancer, ‘Cerviray’, has entered the Indonesian market in 

earnest after completing official license registration with Indonesia’s MOH (Ministry of Health).

Cerviray will be supplied to obstetrics and gynecology and examination centers across the country through Pyridam Farma, a major pharmaceutical company in Indonesia.

After participating in the Incheon Center for Creative Economy & Innovation meetup in September 2020, AIDOT has been conducting clinical trials and verification with local Indonesian companies. Afterwards, through the overseas demonstration test bed project in Indonesia, it completed the local setting of all systems, including the Amazon Web Services (AWS) 

cloud system, as well as the Cerviray AI verification through Pyridam Farma and the local obstetrics and gynecology network.

Indonesia is made up of about 18,000 islands, of which about 6,000 are inhabited. In Indonesia, cervical cancer ranks first in incidence among female cancers, and considerable efforts are being made to eradicate cervical cancer at the national level.

AIDOT Ahra Cho, the manager of global sales and marketing team said, "In light of Indonesia's geographical conditions and environment, Cerviray has been confirmed to be the best 

solution for early cervical cancer screening system in the region, and we will do our best to support and strive to fight cervical cancer in Indonesia." 

AIDOT CEO Jae-hoon Jeong said, “The successful entry into Indonesia served as an opportunity for Korea’s excellent AI medical information and communication technology (ICT) to 

be recognized once again in the global market.” As the signing and licensing and registration work is nearing the end, tangible results will come out within this year,” he said.

CEO Jeong also added, "Contracts and projects have also begun in Bolivia, South America, including CIS countries such as Uzbekistan. Based on these achievements, we will build a 

strong pipeline to further advance AI medical solutions owned by AIDOT."

19th. Apr. 2022. / Korea Economic Daily / Reporter Joon-Sik Park